Recent news on Sevelamer Hydrochloride

Genzyme Reports Significant Revenue and Earnings Growth in First ...  -  Apr 25, 2007
WebWire (press release),Within the Renal business, sales of Renagel® (sevelamer hydrochloride) grew 16 percent to $137.4 million, up from $118.7 million in the first quarter a year

Genzyme Reports Significant Revenue and Earnings Growth in First ...  -  26 Apr 2007
WebWire (press release),Within the Renal business, sales of Renagel® (sevelamer hydrochloride) grew 16 percent to $137.4 million, up from $118.7 million in the first quarter a year

Genzyme completes study on Sevelamer Carbonate in patients with ...  -  Apr 18, 2007
News-Medical.net,The drug was well tolerated with a safety profile consistent with the clinical experience of patients on dialysis using Renagel(R) (sevelamer hydrochloride)

Genzyme Reports Financial Results for Fourth Quarter of 2006 and ...  -  Feb 14, 2007
WebWire (press release),Sales of Renagel® (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, are expected to reach $580-$590

Genzyme Files for Approval of Sevelamer Carbonate for Patients on ...  -  Jan 4, 2007
Oxfordshire Bioscience Network (press release),Renvela is being developed as a next generation phosphate binder to replace Renagel® (sevelamer hydrochloride), the most-prescribed phosphate binder in the

Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude ...  -  Jan 10, 2007
Oxfordshire Bioscience Network (press release),Within the Renal business, Genzyme markets Renagel® (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis,

Renagel in New Dialysis Study Published in Kidney International  -  Jan 15, 2007
DG NewsThe US-based National Kidney Foundation's 2003 K/DOQI guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommend sevelamer hydrochloride

Genzyme Files For Approval Of Sevelamer Carbonate For Patients On ...  -  Dec 23, 2006
Medical News Today (press release),Renvela is being developed as a next generation phosphate binder to replace Renagel(R) (sevelamer hydrochloride), the most-prescribed phosphate binder in

Water conservation work brings award for firm  -  Dec 5, 2006
Cambridge Evening News,...first entry into these awards, the company was also highly recommended for Best Process Plant in relation to its manufacture of sevelamer hydrochloride.

Genzyme Reports Strong Third-Quarter Financial Results  Oct 12, 2006
Within the Renal business, Genzyme markets Renagel® (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis ... -Yahoo! News (press release) Genzyme Reports Strong Third-Quarter Financial Results  Oct 12, 2006
Within the Renal business, Genzyme markets Renagel(R) (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis ... -Drug Newswire (press release), Water conservation work brings award for firm  -  Dec 5, 2006
Cambridge Evening News,...first entry into these awards, the company was also highly recommended for Best Process Plant in relation to its manufacture of sevelamer hydrochloride.

Finding Presented at American Society of Nephrology Annual Meeting  -  Nov 17, 2006
Oxfordshire Bioscience Network (press release),...(Nasdaq: GENZ) announced today that patients using Renagel® (sevelamer hydrochloride) experienced lower rates of hospitalization, fewer days in the hospital

Decreased Hospitalizations and Health Care Costs Associated with ...  -  Nov 16, 2006
Drug Newswire (press release),The National Kidney Foundation's 2003 K/DOQI guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommend sevelamer hydrochloride as a

Fresenius Medical Care Announces Positive Results from PhosLo CARE ...  -  Nov 22, 2006
PipelineReview.com (press release),...there is no difference in cardiovascular calcification between patients treated with PhosLo and those treated with Renagel (sevelamer hydrochloride).

Study of Tolevamer for C. difficile-Associated Diarrhea Published ...  Aug 16, 2006
Renagel(R) (sevelamer hydrochloride) controls serum phosphorus in patients with chronic kidney disease on dialysis, and WelChol(R) (colesevelam hydrochloride ... -DG News

Results of Phase 2 Study of Tolevamer for C. difficile-Associated ...  Aug 16, 2006
Renagel® (sevelamer hydrochloride) controls serum phosphorus in patients with chronic kidney disease on dialysis, and WelChol® (colesevelam hydrochloride ... -Oxfordshire Bioscience Network

Genzyme given green light to make kidney drug at Irish plant  Aug 14, 2006
Waterford is already the primary tabletting and bottling centre for Renagel (sevelamer hydrochloride) – a drug used in patients with chronic kidney disease ... -In-PharmaTechnologist.com

American Kidney Fund, Genzyme Announce New Medicare Part D ...  Jul 31, 2006
...announced today that they have launched a new program to provide Renagel® (sevelamer hydrochloride) free of charge to patients who are enrolled in a Medicare ... -WebWire

Nabi Biopharmaceuticals Releases New Data Which Demonstrate ...  Jul 19, 2006
...constant with Lipitor, there will be no difference in cardiovascular calcification in patients treated with PhosLo versus Renagel(R) (sevelamer hydrochloride). ... -Medical News Today

Delivers Solid Earnings Growth Based on Strong Top-Line ...  Jul 18, 2006
Within the Renal division, revenue for Renagel® (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, grew ... -Oxfordshire Bioscience Network

Fosrenol(R) Demonstrates Effective Phosphate Control With as Few ...  Jul 18, 2006
...in dialysis patients previously receiving other monotherapies or combined phosphate binders, including calcium carbonate and sevelamer hydrochloride(1). The ... -Antara

FOSRENOL® demonstrates effective phosphate control with as few as ...  Jul 19, 2006
...in dialysis patients previously receiving other monotherapies or combined phosphate binders, including calcium carbonate and sevelamer hydrochloride 1. The data ... -PipelineReview.com

Genzyme Reports Second-Quarter Financial Results  Jul 12, 2006
Product Sales Within the Renal division, revenue for Renagel(R) (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on ... -PR Newswire

Genzyme Reports Second-Quarter Financial Results  Jul 12, 2006
Within the Renal division, revenue for Renagel(R) (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, grew ... -Drug Newswire



Genzyme Reports Financial Results for the First Quarter of 2006  Apr 19, 2006
Within the Renal division, revenue for Renagel(R) (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, was ... - MSN Money

Fosrenol Significantly Reduces Tablet Burden for End-Stage Renal ...  Apr 21, 2006
Both patients and physicians preferred Fosrenol (lanthanum carbonate) over sevelamer hydrochloride (HCI) and calcium-based phosphate binders in a naturalistic ... - DG News

Forsenol reduces tablet burden on end stage renal disease patients ...  Apr 26, 2006
Both patients and physicians preferred FOSRENOL (lanthanum carbonate) over sevelamer hydrochloride (HCI) and calcium-based phosphate binders in a naturalistic ... - News-Medical.net

Genzyme's First-Quarter Sales Below Expectations  Apr 19, 2006
...stock than with some others," he added, referring to 2001's inventory screw-up and temporary shortage of Renagel (sevelamer hydrochloride), Genzyme's phosphate ... - BioWorld Online (subscription)





Genzyme Reports Financial Results for Fourth Quarter of 2005 and ...  Feb 15, 2006
Revenue for Renagel® (sevelamer hydrochloride) for patients with end-stage renal disease is expected to reach $495-$505 million this year, compared with $417 ... - WebWire,

Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue  Jan 9, 2006
Fourth-quarter revenue for Renagel(R) (sevelamer hydrochloride), a phosphate binder for patients with end-stage kidney disease on hemodialysis, grew 12 percent ... - MSN Money

GENZYME: Pipeline Highlights  Jan 12, 2006
Enrollment has been completed in a trial evaluating the product's equivalence to sevelamer hydrochloride for patients with end-stage renal disease. ... - Webbolt Business News (subscription)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional